Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis

2002/05/01 by N Ray-Chaudhuri, Neeta Ray-Chaudhuri · 18 citations
Medicine · #Vasculitis and related conditions #IgG4-Related and Inflammatory Diseases #Otitis Media and Relapsing Polychondritis

paper · pdf · doi:10.1136/bjo.86.5.530

Abstract

AIM: To examine the effect of up to 6 weeks of corticosteroid treatment on the positive temporal artery biopsy rate in giant cell arteritis (GCA). METHODS: Prospective comparative clinical study of 11 patients meeting the American College of Rheumatology criteria for diagnosis of GCA. Patients underwent temporal artery biopsy within 1 week, at 2-3 weeks, or after 4 weeks of corticosteroid treatment. RESULTS: Overall, nine of 11 (82%) patients had positive temporal artery biopsies. Six of seven (86%) biopsies performed after 4 or more weeks of steroid treatment were positive. CONCLUSION: Temporal artery biopsy is useful several weeks after institution of steroids.

Citations

• The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
• Skip Areas in Temporal Arteritis

Cited by

• Riesenzellarteriitis. Ätiologische Erkenntnisse und diagnostische Herausforederung für den Pathologen
• A stroke of bad luck. [europepmc]
• Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. [europepmc]
• A Stab in the Dark: A Case Report of an Atypical Presentation of Giant Cell Arteritis (GCA). [europepmc]
• Diagnostic Performance of a Temporal Artery Biopsy for the Diagnosis of Giant Cell Arteritis in Japan-A Single-center Retrospective Cohort Study. [europepmc]
• Fever as the Sole Presentation of Giant Cell Arteritis: A Near Miss. [europepmc]
• Diagnosis and Management of Rare Immune-Related Adverse Events. [europepmc]
• Giant Cell Arteritis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. [europepmc]
• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. [europepmc]
• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. [europepmc]
• Utilization of the Revised American College of Rheumatology (rACR) Scoring to Avoid Unnecessary Temporal Artery Biopsies-A Case Series. [europepmc]
• Role of Temporal artery biopsy in a sequential Giant Cell Arteritis fast-track pathway: a 5-year prospective study. [europepmc]
• Multimodality Imaging in Cranial Giant Cell Arteritis: First Experience with High-Resolution T1-Weighted 3D Black Blood without Contrast Enhancement Magnetic Resonance Imaging. [europepmc]
• Halo sign on temporal artery ultrasound versus temporal artery biopsy for giant cell arteritis. [europepmc]
• Temporal artery biopsy in giant cell arteritis: clinical perspectives and histological patterns. [europepmc]
• Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies. [europepmc]
• Simultaneous Bilateral Central Retinal Artery Occlusions: Partial Recovery With Multimodal Therapy. [europepmc]
• Temporal artery ultrasound versus temporal artery biopsy for giant cell arteritis [europepmc]

Related

• The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
• Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes
• Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database
• Repetitive 18F‐fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients
• French protocol for the diagnosis and management of giant cell arteritis